首頁 > 市場調查報告書 > 製藥

生物製劑分子標靶治療學

市場調查報告書

商品編碼

1289772

全球抗體藥物結合物市場 - 2023-2030年

Global Antibody Drug Conjugates Market - 2023-2030

出版日期: 2023年06月12日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概況

全球抗體藥物結合物市場規模在2022年達到50.328億美元，預計到2030年將出現有利可圖的成長，達到165.946億美元。在預測期間（2023-2030年），該市場的年復合成長率為16.6%。

全球抗體藥物結合物市場的驅動因素包括：癌症發病率的增加，對癌症相關研究和開發的投資增加，癌症的創新和靶向治療方案的增加，以及抗體工程和結合技術的進步。

市場動態

癌症發病率的增加

癌症發病率的增加是在預測期內推動市場佔有率的一個主要因素。全球癌症發病率的增加促使了更多的病人需要有效的治療。 ADCs通過直接向癌細胞傳遞細胞毒性載荷，提供了一種有針對性的癌症治療方法，可能會改善治療效果。隨著癌症患者人數的增加，對ADC這樣的創新和有效療法的需求也越來越大。

傳統的癌症治療方法，如化療、放療和手術，在療效和耐受性方面都有局限性。通過將單克隆抗體的特異性與化療藥物的細胞毒性作用相結合，ADCs已顯示出更高的療效。它們可以選擇性地靶向癌細胞，而不傷害健康細胞，從而改善治療效果。癌症發病率的增加使得開發和採用更有效的治療方法成為必要，這使得ADCs成為一種有希望的解決方案。

ADCs的高生產成本和副作用

在預測期內，與抗體藥物結合相關的高生產成本和副作用是阻礙市場佔有率的一個主要因素。 ADC的開發和製造涉及複雜的過程，包括單克隆抗體的生產、共軛化學、純化和配方。這些過程需要專門的基礎設施、專業知識和資源，促使生產成本高。

生產ADC的高成本會限制它們的可及性和可負擔性，特別是在預算有限的醫療系統或資源有限的地區。 ADC的成本也可能成為醫療支付方報銷的障礙，進一步影響市場佔有率。

ADC的設計是為了將細胞毒劑選擇性地傳遞給癌細胞，但它們仍然可能引起脫靶效應和副作用。常見的副作用包括血液學毒性、肝臟毒性、免疫原性和輸液相關反應。副作用和安全問題會影響患者對ADC的接受程度、治療依從性和市場應用，因此減少副作用和提高安全性非常重要。

COVID-19影響分析

COVID-19大流行對抗體藥物結合物市場產生了重大影響。該大流行病造成的全球供應鏈中斷影響了ADC的生產和供應。封鎖、旅行限制和檢疫措施擾亂了物流和運輸，促使原料、試劑和成品的延誤和短缺。供應鏈的中斷已經影響了ADC的製造能力、庫存水平和交付時間。

這場大流行還促使了ADC臨床試驗的延遲或暫停。醫療保健系統、臨床試驗主辦方和監管機構的重點已轉向解決大流行病，促使正在進行的臨床試驗的延遲和中斷。延遲的臨床試驗會影響監管部門的批准時間和ADC的市場進入。

俄烏衝突分析

俄烏衝突對抗體藥物結合市場產生了負面影響。如果衝突升級並促使政治不穩定，它可能會擾亂包括ADC在內的全球醫藥產品供應鏈。烏克蘭是醫藥原料生產的重要參與者，擁有強大的製藥業。

供應鏈的任何中斷，如出口限制、運輸中斷或政治不穩定，都可能影響ADC生產所需原料和成分的供應，有可能促使供應短缺並影響市場。

烏克蘭和俄羅斯對國際癌症臨床試驗作出了重大貢獻。烏克蘭的局勢將對進行臨床試驗產生各種影響，但它主要影響到治療設施的關閉、國內流離失所和被迫移民。

Market Overview

The Global Antibody Drug Conjugates Market size reached US$ 5,032.8 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 16,594.6 million by 2030. The market is exhibiting at a CAGR of 16.6% during the forecast period (2023-2030).

The global antibody drug conjugates market is driven by factors such as the increasing prevalence of cancer, growing investments in research and developments related to cancer, increasing innovative and targeted treatment options for cancer, and advancements in antibody engineering and conjugation technologies.

Market Dynamics

Increasing Prevalence Of Cancer

The increasing prevalence of cancer is a major factor driving the market share during the forecast period. The increasing incidence of cancer globally has resulted in a larger patient population in need of effective treatments. ADCs offer a targeted approach to cancer therapy by delivering cytotoxic payloads directly to cancer cells, potentially improving treatment outcomes. As the number of cancer patients rises, there is a greater demand for innovative and effective therapies like ADCs.

Traditional cancer treatments, such as chemotherapy, radiation therapy, and surgery, have limitations in terms of efficacy and tolerability. ADCs have demonstrated enhanced efficacy by combining the specificity of monoclonal antibodies with the cytotoxic effects of chemotherapy drugs. They can selectively target cancer cells while sparing healthy cells, leading to improved treatment outcomes. The increasing prevalence of cancer necessitates the development and adoption of more effective treatments, positioning ADCs as a promising solution.

High Production Cost & Side Effects of ADCs

High production costs and side effects associated with antibody drug conjugations is a major factor hampering the market share during the forecast period. The development and manufacturing of ADCs involve complex processes, including the production of monoclonal antibodies, conjugation chemistry, purification, and formulation. These processes require specialized infrastructure, expertise, and resources, resulting in high production costs.

The high cost of producing ADCs can limit their accessibility and affordability, especially in healthcare systems with budget constraints or regions with limited resources. The cost of ADCs can also be a barrier to reimbursement by healthcare payers, further impacting market share.

ADCs are designed to deliver cytotoxic agents selectively to cancer cells, but they can still cause off-target effects and side effects. Common side effects include hematological toxicity, liver toxicity, immunogenicity, and infusion-related reactions. Side effects and safety concerns can impact patient acceptance, treatment compliance, and market adoption of ADCs, so it is important to reduce side effects and enhance safety profiles.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the antibody drug conjugates market. The global supply chain disruptions caused by the pandemic have affected the production and availability of ADCs. Lockdowns, travel restrictions, and quarantine measures have disrupted logistics and transportation, resulting in delays and shortages in raw materials, reagents, and finished products. The disruptions in the supply chain have impacted the manufacturing capacity, inventory levels, and delivery timelines of ADCs.

The pandemic has also led to the delay or suspension of clinical trials of ADCs. The focus of healthcare systems, clinical trial sponsors, and regulatory agencies has shifted towards addressing the pandemic, leading to delays and disruptions in ongoing clinical trials. Delayed clinical trials can affect the regulatory approval timelines and market entry of ADCs.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict negatively impacted the antibody drug conjugation market. If the conflict escalates and leads to political instability, it can disrupt the global supply chain for pharmaceutical products, including ADCs. Ukraine is a significant player in the production of pharmaceutical ingredients and has a robust pharmaceutical industry.

Any disruptions in the supply chain, such as export restrictions, transportation disruptions, or political instability, could affect the availability of raw materials and components needed for ADC production, potentially leading to supply shortages and impacting the market.

Significant contributions are made by Ukraine and Russia to international cancer clinical trials. The situation in Ukraine will have a variety of effects on performing clinical trials, but it mainly affects the closure of treatment facilities, internal displacement, and forced migration.

Segment Analysis

The global antibody drug conjugates market is segmented based on application, technology, and region.

Based On Application, The Breast Cancer Segment Dominates The Market Share

Based on application, the breast cancer segment dominates the market share of around 48.6% during the forecast period. Breast cancer has a high incidence rate worldwide, making it a significant public health concern. The increasing prevalence of breast cancer contributes to the larger patient population in need of effective treatment options. As a result, there is a strong demand for targeted therapies, such as ADCs, for the treatment of breast cancer.

ADCs offer a targeted treatment approach for breast cancer by selectively delivering cytotoxic payloads to cancer cells expressing specific antigens, such as HER2 or estrogen receptors. This targeted approach enhances treatment efficacy and reduces toxicity compared to traditional chemotherapy. The ability of ADCs to address specific molecular targets in breast cancer makes them a favorable choice for clinicians and patients.

Geographical Analysis

North America Holds The Largest Market Share Due To The Increasing R&D on ADC Products

North America holds the largest market share of about 51.4% during the forecast period due to the increasing R&D on ADC. North America, particularly the United States, has a strong focus on research and development in the pharmaceutical industry. Many leading pharmaceutical companies, biotechnology firms, and academic institutions in North America are actively engaged in ADC research and development.

Competitive Landscape

The major global players in the market include: Takeda Pharmaceutical Company Ltd., Hoffmann-La Roche, Pfizer, AstraZeneca, Gilead Sciences, Seagen, Astellas Pharma, Daiichi Sankyo Company, GlaxoSmithKline, and ADC Therapeutics.

Why Purchase the Report?

To visualize the global antibody drug conjugates market segmentation based on application, technology, and region, and understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of antibody drug conjugates market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The global antibody drug conjugates market report would provide approximately 54 tables, 46 figures, and 195 pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Application
3.2. Snippet by Technology
3.3. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing prevalence of cancer
- 4.1.2. Restraints
  - 4.1.2.1. High production cost & side effects of ADCs
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer's Strategic Initiatives
6.6. Conclusion

7. By Application

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 7.1.2. Market Attractiveness Index, By Application
7.2. Breast cancer*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Blood cancer
7.4. Skin cancer
7.5. Lung cancer
7.6. Ovary cancer
7.7. Others

8. By Technology

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 8.1.2. Market Attractiveness Index, By Technology
8.2. Non-cleavable linker*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Cleavable linker
8.4. Linker less

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.2.5.1. The U.S.
  - 9.2.5.2. Canada
  - 9.2.5.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.5.1. Germany
  - 9.3.5.2. The UK
  - 9.3.5.3. France
  - 9.3.5.4. Italy
  - 9.3.5.5. Spain
  - 9.3.5.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.4.5.1. Brazil
  - 9.4.5.2. Argentina
  - 9.4.5.3. Rest of South America
9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.5.5.1. China
  - 9.5.5.2. India
  - 9.5.5.3. Japan
  - 9.5.5.4. Australia
  - 9.5.5.5. Rest of Asia-Pacific
9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

11.1. Takeda Pharmaceutical Company Ltd.*
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Financial Overview
- 11.1.4. Key Developments
11.2. Hoffmann-La Roche Ltd.
11.3. Pfizer Inc.
11.4. AstraZeneca
11.5. Gilead Sciences Inc.
11.6. Seagen Inc.
11.7. Astellas Pharma
11.8. Daiichi Sankyo Company Ltd.
11.9. GlaxoSmithKline Plc
11.10. ADC Therapeutics

LIST NOT EXHAUSTIVE